comlogo01.svg comlogo01.svg

f4banner1.jpg f4bannerph1.jpg

Partnering

At Full-Life we are passionate about discovering, developing and delivering life-changing radiotherapeutics to cancer patients world wide. With our goal to provide new therapies to people with unmet medical need, we are seeking strategic partnerships with leading biopharma innovators to support us on our mission.

Business Development

  • f4img1.jpg
    Our Partnering Focus

    Strategic collaborations surrounding our pipeline of innovative RDC programs

    Platform discovery partnerships leveraging our Clear-X & Res-X technologies

    In-licensing opportunities to complement our in-house pipeline

  • f4img11.jpg
    Our Preferred Partners

    Bring complementary capabilities to jointly advance our assets through development towards commercialization

    Have a vision for maximizing value of our assets

    Recognize our expertise in clinical trial execution, RDC manufacturing & logistics to jointly bring innovative medicines to patients

f4imgpc14-7.jpg f4imgpg1.jpg
Click

Holistic Approach

To enhance our long-term strategy and maximize our company's asset value, our corporate and business development team systematically evaluates collaboration opportunities with diverse global and regional stakeholders in the biopharmaceutical and biotech industries.

Contact Us

If you are interested in joining forces with Full-Life, please contact us at BD@t-full.com

Read More
f4img5.png

Oliver Froescheis

Senior Vice President, Corporate Development

Dr. Froescheis joins us with 25 years of experience in the pharmaceutical and biotech industry. Prior to Full-Life, Oliver served as Senior Vice President, Corporate and Business Development at Compugen, a clinical-stage drug discovery and development company. Oliver started his industry career in 1998 at Roche, where he held positions with increasing responsibility in research, project management, and business development. During his tenure in biopharma, he led and contributed to numerous strategic transactions encompassing M&A as well as in- and out-licensing technology and asset deals. Oliver is a chemist by training and received his Ph.D. in Analytical Chemistry from the University of Ulm, Germany.